Translating Research into Next Generation Care Through Collaboration


Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Read More About Us

Enterprise Innovation Metrics from FY20 to FY24

535
New Tech Disclosures
197
Issued US Patents
129
Licenses and Options
20
NewCo Launches

  

  

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

We also provide access to a diverse selection of tangible materials developed by Weill Cornell Medicine investigators. See the most updated catalog of our ready-for-licensing tangible materials PDF icon here.

  

Testimonials

Dr. John Leonard
John P. Leonard, M.D., Senior Associate Dean of Innovation and Initiatives
Getting new innovations across the finish line requires collaboration, often with industry partners, to scale up findings for application in healthcare. Ultimately, we want the work we do here to have a real impact on patients. By fostering an entrepreneurial environment, we can do that.
Lisa Placanica, Ph.D.
Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing
There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.
Randi Silver, Ph.D.
Randi B. Silver, Ph.D., Associate Dean and Professor of Physiology and Biophysics
Enterprise Innovation has galvanized us to move forward as basic scientists, and to look for translational aspects that could be developed, with an industrial partner, for patient care. As a result, we have been able to get traction in exploring various avenues for commercialization with angel investors, pharma, venture capital and, significantly, our own Tri-Institutional Therapeutics Discovery Institute, none of which would have been possible without support from the Daedalus Fund for Innovation.
Dr. Ronald Crystal
Ronald G. Crystal, M.D., Chair of Genetic Medicine and Professor of Medicine
Allying with the right industrial partner is a vital factor in attracting investors, and Enterprise Innovation’s relationships with and access to biopharma and life science leaders make it possible for aspiring scientist/entrepreneurs to find the right match.

The Power of Partnership in Innovation

April 14, 2025

Nearly 200 scientists, investors and industry representatives attended Weill Cornell Medicine’s 2025 Biomedical Innovation Conference (“BioInnovate”) April 1, sharing their startup journeys and experiences nurturing biomedical advances into health care products and companies.

New Strategy May Enable Cancer Monitoring from Blood Tests Alone

April 11, 2025

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators. The method, based on whole-genome sequencing of DNA, also represents an important step toward the goal of routine blood test-based screening for early cancer detection.